gallus 840 420

Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody

In Press Release by CecileLeave a Comment

gallus 840 420

August 21st, 2014

Gallus BioPharmaceuticals, LLC, a premier, full service biopharmaceutical contract development and manufacturing organization (CMO) announced today that it has been selected by Progenics Pharmaceuticals, Inc., an oncology company focused on the development of innovative approaches to targeting and treating cancer, to manufacture the anti-prostate specific membrane antigen (PSMA) monoclonal antibody used in Progenics’ PSMA ADC product candidate. Under the agreement the antibody will be produced in Gallus’ commercial manufacturing facility in St. Louis, Missouri.

“Our extensive commercial manufacturing experience and proven quality systems make Gallus an ideal partner to support Progenics in the manufacture of their anti-PSMA antibody,” said Mark R. Bamforth, President & CEO of Gallus. “We look forward to working with Progenics as they advance this treatment for patients with prostate cancer.”

PSMA ADC is a fully human monoclonal antibody-drug conjugate designed to deliver chemotherapeutic drug selectively to prostate cancer cells. It does so by targeting the three-dimensional structure of PSMA, a protein that is a clinically validated biomarker of prostate cancer which is expressed on the surface of prostate cancer cells. The PSMA antibody produced at Gallus is designed to internalize into the cancer cell, release active anti-cancer drug, and destroy the malignant cell.

“Gallus has impressed us with their ability to meet our high standards, combined with the experience and expertise necessary to manufacture our anti-PSMA antibody,” said Nitya Ray, PhD, Sr. Vice President, Manufacturing of Progenics. “We look forward to a productive partnership with Gallus as we develop this product for patients in need of this therapy.”

Leave a Comment

Current ye@r *